45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
10,227
Insurances with rates
10
CPT / HCPCS codes
7,404
Source MRF
Most expensive procedures (gross)
J0225
$501,274
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
J0225
$501,274
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
A9513
$199,500
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
A9513
$199,500
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
J1823
$183,400
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J1823
$183,400
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J2351
$173,384
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
J2351
$173,384
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
C9293
$172,931
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
C9293
$172,931
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
J9228
$149,137
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J9228
$149,137
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J1747
$107,379
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J1747
$107,379
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J2327
$90,720
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2327
$90,720
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2350
$82,800
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J2350
$82,800
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J9309
$75,891
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J9309
$75,891
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J0638
$71,920
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J0638
$71,920
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J9334
$66,247
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J9334
$66,247
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J3241
$64,981
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J3241
$64,981
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J2507
$64,621
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J2507
$64,621
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J9298
$61,036
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J9298
$61,036
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J1628
$59,038
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J1628
$59,038
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J3245
$55,935
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3245
$55,935
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3357
$50,801
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J3357
$50,801
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J9042
$49,316
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9042
$49,316
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9272
$47,613
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9272
$47,613
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9043
$47,423
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9043
$47,423
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9022
$47,258
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J9022
$47,258
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J1640
$45,950
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J1640
$45,950
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J9144
$44,180
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J9144
$44,180
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J2329
$43,985
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
J2329
$43,985
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $501,274 | $538,571 | $584,820 | 19 |
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $501,274 | $364,021 | $808,126 | 32 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $199,500 | $214,344 | $232,750 | 19 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $199,500 | $144,875 | $321,623 | 32 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $183,400 | $197,046 | $213,966 | 19 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $183,400 | $133,183 | $295,667 | 32 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $173,384 | $186,285 | $202,281 | 19 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $173,384 | $125,910 | $279,520 | 32 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $172,931 | $185,798 | $201,753 | 19 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $172,931 | $125,581 | $278,789 | 32 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $149,137 | $160,233 | $173,993 | 19 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $149,137 | $108,302 | $240,430 | 32 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $107,379 | $115,369 | $125,276 | 19 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $107,379 | $77,978 | $173,111 | 32 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $90,720 | $97,470 | $105,840 | 19 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $90,720 | $65,880 | $146,254 | 32 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $82,800 | $88,961 | $96,600 | 19 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $82,800 | $60,129 | $133,486 | 32 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $75,891 | $81,538 | $88,540 | 19 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $75,891 | $55,111 | $122,347 | 32 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $71,920 | $77,271 | $83,906 | 19 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $71,920 | $52,227 | $115,945 | 32 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $66,247 | $71,176 | $77,288 | 19 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $66,247 | $48,108 | $106,799 | 32 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $64,981 | $69,816 | $75,811 | 19 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $64,981 | $47,188 | $104,758 | 32 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $64,621 | $69,429 | $75,391 | 19 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $64,621 | $46,927 | $104,179 | 32 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $61,036 | $65,578 | $71,209 | 19 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $61,036 | $44,324 | $98,399 | 32 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $59,038 | $63,430 | $68,877 | 19 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $59,038 | $42,873 | $95,177 | 32 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $55,935 | $60,097 | $65,257 | 19 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $55,935 | $40,619 | $90,175 | 32 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $50,801 | $54,581 | $59,268 | 19 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $50,801 | $36,891 | $81,898 | 32 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $49,316 | $52,986 | $57,536 | 19 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $49,316 | $35,813 | $79,505 | 32 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $47,613 | $51,155 | $55,548 | 19 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $47,613 | $34,576 | $76,759 | 32 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $47,423 | $50,952 | $55,327 | 19 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $47,423 | $34,438 | $76,453 | 32 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $47,258 | $50,774 | $55,134 | 19 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $47,258 | $34,318 | $76,186 | 32 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $45,950 | $49,369 | $53,608 | 19 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $45,950 | $33,369 | $74,078 | 32 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $44,180 | $47,467 | $51,543 | 19 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $44,180 | $32,083 | $71,224 | 32 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $43,985 | $47,257 | $51,315 | 19 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $43,985 | $31,941 | $70,909 | 32 |
Showing top 50 of 10,227 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.